natgillin/translations-raw huggingface dataset:
The preclinical safety profile of pazopanib was assessed in mice, rats, rabbits and monkeys. 
Neklinički profil sigurnosti primjene pazopaniba procjenjivan je u miševa, štakora, zečeva i majmuna.
If the concomitant administration of an H2-receptor antagonist is medically necessary, pazopanib should be taken without food at least 2 hours before or at least 10 hours after a dose of an H2-receptor antagonist. 
Ukoliko je istodobna primjena antagonista H2 receptora medicinski neophodna, pazopanib treba uzeti bez hrane najmanje 2 sata prije ili najmanje 10 sati nakon doze antagonista H2 receptora.
In the cytokine pre-treated subgroup, the majority (75%) had received interferon-based treatment. 
U skupini ranije liječenih citokinima, većina (75%) je primala terapiju temeljenu na interferonu.
Prior anthracycline therapy may be a risk factor for cardiac dysfunction. 
Prethodno liječenje antraciklinima može biti čimbenik rizika za disfunkciju srca.
Please consult your doctor or nurse for advice. 
Savjetujte se sa svojim liječnikom ili medicinskom sestrom.
Effect of concomitant use of pazopanib and simvastatin 
Učinak istodobne uporabe pazopaniba i simvastatina
Ninety-eight percent (98%) of subjects received prior doxorubicin, 70% prior ifosfamide, and 65% of subjects had received at least three or more chemotherapeutic agents prior to study enrolment. 
Devedeset i osam posto (98%) bolesnika prethodno je primilo doksorubicin, 70% ifosfamid, a njih 65% primilo je najmanje tri ili više kemoterapijskih lijekova prije uključenja u ispitivanje.
Frequency (all grades) 
Učestalost (svi stupnjevi)
Tell your doctor if you notice significant weight gain or tiredness. 
Recite svom liječniku ako primijetite značajno povećanje tjelesne težine ili umor.
Pazopanib should not be used in children younger than 2 years of age because of safety concerns with regard to organ growth and maturation (see sections 4.4 and 5.3). 
Pazopanib se ne smije primjenjivati u djece mlađe od 2 godine zbog sigurnosnih razloga vezanih uz rast i sazrijevanje organa (vidjeti dijelove 4.4 i 5.3).
From the total of 435 patients in this study, 233 patients were treatment-naïve and 202 were second-line patients who had received one prior IL-2 or INF-based therapy. 
Od ukupno 435 bolesnika u ovom ispitivanju, 233 bolesnika nije ranije primalo terapiju, a 202 bolesnika druge linije je ranije primilo jednu IL-2 ili INF-baziranu terapiju.
Risk factors 
Čimbenici rizika
If you forget to take Votrient Do not take a double dose to make up for a forgotten dose. 
Nemojte uzeti dvostruku dozu kako bi nadoknadili zaboravljenu dozu.
OS = overall survival * Overall survival for the respective STS histological subgroups (leiomyosarcoma, synovial sarcoma and “Other” STS) should be interpreted with caution due to the small number of subjects and wide confidence intervals 
OS = sveukupno preživljenje Sveukupno preživljenje za navedene STS histološke podgrupe (leiomiosarkom, sinovijalni sarkom i „ostali“ sarkomi) treba interpretirati s oprezom zbog malog broja ispitanika i širokih intervala pouzdanosti
Table 2 Treatment-related adverse reactions reported in RCC studies (n = 1149) or during post-marketing period 
Tablica 2 Nuspojave povezane s liječenjem prijavljene u ispitivanjima RCC-a (n=1149) ili nakon stavljanja lijeka u promet
Thirteen of the 15 subjects in the pazopanib arm of the STS Phase III study had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk by increasing cardiac after-load. 
Trinaest od 15 ispitanika u kraku s pazopanibom u ispitivanju STS-a faze III imalo je istodobno hipertenziju koja je možda pogoršala disfunkciju srca u rizičnih bolesnika, povećanjem naknadnog opterećenja srca.
Other key eligibility criteria of the VEG110727 study were: histological evidence of high or intermediate grade malignant STS and disease progression within 6 months of therapy for metastatic disease, or recurrence within 12 months of (neo) -/adjuvant therapy. 
Ostali ključni kriteriji VEG110727 ispitivanja bili su: histološki dokaz malignog STS-a visokog ili srednjeg stupnja i progresija bolesti unutar 6 mjeseci od liječenja metastatske bolesti, ili povratak bolesti unutar 12 mjeseci od (neo)adjuvantnog liječenja.
Votrient can make some conditions worse or cause serious side effects. 
Votrient može pogoršati neka stanja ili izazvati ozbiljne nuspojave.
Don't take Votrient with food, as it affects the way the medicine is absorbed. 
Ne uzimajte Votrient s hranom jer utječe na način apsorpcije lijeka.
How to take Votrient 
Kako uzimati Votrient
Votrient has no or negligible influence on the ability to drive and use machines. 
Votrient ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Infections (with or without neutropenia)† 
Infekcije i infestacije često infekcije (s ili bez neutropenije)†
Four of the 15 subjects had full recovery (within 5% of baseline) and 5 had partial recovery (within the normal range, but >5% below baseline). 
Potpuni oporavak imala su četiri od 15 ispitanika (unutar 5% odstupanja od početnih vrijednosti), a 5 ispitanika imalo je djelomični oporavak (unutar normalnog raspona, ali >5% ispod početne vrijednosti).
You must look out for certain symptoms while you are taking Votrient to reduce the risk of any problems. 
Za vrijeme uzimanja lijeka Votrient morate pripaziti na određene simptome kako bi smanjili rizik bilo kakvog problema.
Effect of food on pazopanib 
Učinci hrane na pazopanib
The majority of these cases describe mucositis f Frequency is based on laboratory value tables from VEG110727 (N=240). 
Većina slučajeva opisuje mukozitis f Frekvencija se temelji na tablicama laboratorijskih vrijednosti iz ispitivanja VEG110727 (n=240).
Pazopanib may have a greater impact on SN-38 disposition in subjects with the UGT1A1*28 polymorphism relative to subjects with the wild-type allele. 
Pazopanib možda ima veći utjecaj na SN-38 dispoziciju u ispitanika s UGT1A1*28 polimorfizmom u odnosu na ispitanike s divljim tipom alela.
This can result in weight increase and tiredness. 
To može rezultirati povećanjem tjelesne težine i umorom.
Neutropenia, thrombocytopenia and palmar-plantar erythrodysaethesia syndrome were observed more frequently in patients of East Asian descent. 
Neutropenija, trombocitopenija i sindrom palmarno-plantarne eritrodizestezije češće su primijećeni u bolesnika podrijetlom iz istočne Azije.
Before initiating pazopanib, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm. 
Prije početka primjene pazopaniba potrebno je pažljivo razmotriti ovaj rizik u bolesnika s čimbenicima rizika kao što su hipertenzija ili aneurizma u anamnezi.
Response rate (CR+PR) % (95% CI) Duration of response Median (weeks) (95% CI) 38.9 (16.7, 40.0) 
Stopa odgovora (CR+PR) % (95% CI) Trajanje odgovora Medijan (tjedni) (95% CI) 38,9 (16,7; 40,0)
Votrient is used in adults to treat: - kidney cancer that is advanced or has spread to other organs. 
Votrient se u odraslih koristi za liječenje: - karcinoma bubrega koji je uznapredovao ili se proširio na druge organe.
Medicinal products that raise gastric pH 
Lijekovi koji povisuju želučani pH
Based on in vitro IC50 and in vivo plasma Cmax values, pazopanib metabolites GSK1268992 and GSK1268997 may contribute to the net inhibitory effect of pazopanib towards BCRP. 
Temeljem vrijednosti in vitro IC50 i Cmax in vivo u plazmi, metaboliti pazopaniba GSK1268992 i GSK1268997 mogu doprinijeti ukupnom inhibitornom učinku pazopaniba na BCRP.
See section 4.4 for liver monitoring and dose modification for patients with drug-induced hepatotoxicity. 
Vidjeti dio 4.4 za praćenje funkcije jetre i prilagodbu doze u bolesnika s hepatotoksičnošću uzrokovanom primjenom lijeka.
Patients should avoid driving or using machines if they feel dizzy, tired or weak. 
Bolesnici trebaju izbjegavati upravljanje vozilima i rad sa strojevima ako osjećaju omaglicu, umor ili slabost.
One of these metabolites inhibits the proliferation of VEGF-stimulated human umbilical vein endothelial cells with a similar potency to that of pazopanib, the others are 10- to 20-fold less active. 
Jedan od tih metabolita inhibira proliferaciju endotelnih stanica umbilikalne vene stimuliranih VEGF-om potentnošću sličnom pazopanibu, dok su ostali 10 do 20 puta manje aktivni.
Because the mechanism of action of pazopanib can severely affect organ growth and maturation during early post-natal development in rodents (see section 5.3), pazopanib should not be given to paediatric patients younger than 2 years of age. 
Kako mehanizam djelovanja pazopaniba može ozbiljno utjecati na razvoj i sazrijevanje organa tijekom ranog postanatalnog razvoja u glodavaca (vidjeti dio 5.3), pazopanib se ne smije davati pedijatrijskim bolesnicima mlađim od 2 godine života.
Votrient is not recommended if you are pregnant. 
Votrient se ne preporučuje u trudnoći.
Baseline and periodic evaluation of LVEF is recommended in patients at risk of cardiac dysfunction. 
Početna i povremene procjene LVEF-a se preporučuju u bolesnika s rizikom disfunkcije srca.
OS Overall ITT 
OS Sveukupna ITT
Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, protein kinase inhibitors, ATC code: L01XE11 
Farmakoterapijska skupina: Antineoplastični lijekovi, inhibitori protein kinaze, ATK oznaka: L01XE11
Renal cell carcinoma (RCC) 
Karcinom bubrega (RCC)
The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysm and/or artery dissections. 
Primjena inhibitora VEGF puta u bolesnika s hipertenzijom ili bez nje može potaknuti stvaranje aneurizama i/ili disekcija arterije.
Potential induction of human CYP3A4 was demonstrated in an in vitro human PXR assay. 
Potencijalna indukcija ljudskog CYP3A4 pokazana je in vitro metodom „human PXR assay“.
Elevated blood pressure levels (systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥100 mm Hg) occurred early in the course of treatment (approximately 40% of cases occurred by day 9 and approximately 90% of cases occurred in the first 18 weeks). 
Povišene razine krvnog tlaka (sistolički tlak ≥150 mmHg ili dijastolički tlak ≥100 mmHg) javljale su se rano tijekom razdoblja liječenja (približno 40% slučajeva se javilo u prvih 9 dana i približno 90% se javilo u prvih 18 tjedana).
Tell your doctor or pharmacist if any of these effects become troublesome. 
Recite svom liječniku ili ljekarniku ako bilo koja od ovih nuspojava počne predstavljati problem.
Other observed effects include body weight loss, diarrhoea and/or morbidity that were either secondary to local gastrointestinal effects caused by high local mucosal medicinal product exposure (monkeys) or pharmacological effects (rodents). 
Drugi zabilježeni učinci uključuju gubitak tjelesne težine, proljev i/ili morbiditete koji su bili sekundarni zbog lokalnih gastrointestinalnih učinaka uzrokovanih visokom lokalnom izloženošću sluznice lijeku (u majmuna) ili farmakološkim učincima (u glodavaca).
Votrient can cause separation or tear of the lining of the back part of the eye (retinal detachment or tear). 
Votrient može uzrokovati odvajanje ili razdor ovojnice na stražnjem dijelu oka (odvajanje ili razdor mrežnice).
Post-marketing data on safety and tolerability across all pazopanib clinical studies and from spontaneous reports have also been evaluated. 
Nakon stavljanja lijeka u promet bili su također procijenjeni podaci o sigurnosti i podnošljivosti iz svih kliničkih ispitivanja s pazopanibom i iz spontanih prijava.
Interruption of pazopanib and/or dose reduction should be combined with treatment of hypertension (if present, refer to hypertension warning section above) in patients with significant reductions in LVEF, as clinically indicated. 
Prekid liječenja pazopanibom i/ili smanjenje doze treba kombinirati s liječenjem hipertenzije (ukoliko je prisutna, pogledati upozorenje za hipertenziju u prethodnom dijelu teksta) u bolesnika sa značajnim smanjenjem LVEF-a, prema kliničkoj indikaciji.
The median duration of follow-up of subjects (defined as date of randomisation to date of last contact or death) was similar for both treatment arms (9.36 months for placebo [range 0.69 to 23.0 months] and 10.04 months for pazopanib [range 0.2 to 24.3 months]. 
Srednje vrijeme praćenja ispitanika (definirano kao vrijeme od randomizacije do posljednjeg kontakta ili smrti) bilo je slično za oba ispitivana kraka (9,36 mjeseci za placebo [raspon 0,69 do 23,0 mjeseci] i 10,04 za pazopanib [raspon 0,2 do 24,3 mjeseci].
In addition, concomitant use of pazopanib and other statins should be undertaken with caution as there are insufficient data available to assess their impact on ALT levels. 
Nadalje, potreban je oprez pri istodobnoj primjeni pazopaniba i drugih statina jer su nedostatni podaci kojima se procjenjuje njihov utjecaj na razine ALT-a.
Votrient can cause a tear (perforation) in your stomach or intestinal wall or the development of an abnormal connection between two parts of your digestive tract (a fistula). 
Votrient može uzrokovati razdor (proboj) u Vašem želucu ili crijevnom zidu ili razvoj neuobičajenih spojeva između dva dijela Vašeg probavnog trakta (fistula).
Do not break or crush the tablets as this affects the way the medicine is absorbed and may increase the chance of side effects. 
Nemojte lomiti ili mrviti tablete jer to utječe na način apsorpcije lijeka te može povećati mogućnost pojave nuspojava.
When post-weaning rats were dosed from day 21 post partum to day 62 post partum, toxicological findings were similar to adult rats at comparable exposures. 
Kada su štakori dozirani od 21. do 62. dana nakon rođenja, toksikološki nalazi bili su slični onima u odraslih štakora pri sličnoj izloženosti.
Median (months) Response rate 
Medijan (mjeseci) Stopa odgovora
Swelling of the brain (reversible posterior leukoencephalopathy syndrome) Votrient can, on rare occasions, cause swelling of the brain, which may be life threatening. 
Oticanje mozga (sindrom reverzibilne posteriorne leukoencefalopatije) Votrient u rijetkim slučajevima može uzrokovati oticanje mozga, koje može biti opasno po život.
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG12 0DJ, United Kingdom. 
Glaxo Operations UK Ltd (posluje kao Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG120DJ, Ujedinjeno Kraljevstvo
Stop taking Votrient and seek medical help immediately if you get any of these symptoms, or if you get headache accompanied with any of these symptoms. 
Prestanite uzimati Votrient i odmah potražite liječničku pomoć u slučaju pojave bilo kojega od navedenih simptoma ili glavobolje praćene nekim od tih simptoma.
Soft-tissue sarcoma (STS) 
Sarkom mekih tkiva (STS)
Blood pressure should be monitored and managed promptly using a combination of anti-hypertensive therapy and dose modification of pazopanib (interruption and re-initiation at a reduced dose based on clinical judgement) (see sections 4.2 and 4.8). 
Krvni tlak treba kontrolirati te brzo korigirati primjenom antihipertenzivne terapije i modifikacijom doze pazopaniba (prekid i ponovni početak liječenja smanjenom dozom na temelju kliničke procjene) (vidjeti dijelove 4.2 i 4.8).
The active metabolite of irinotecan, SN-38, is a substrate for OATP1B1 and UGT1A1. 
Aktivni metabolit irinotekana, SN-38, supstrat je za OATP1B1 i UGT1A1.
It should be taken without food, at least one hour before or two hours after a meal (see section 5.2). 
Treba se uzimati bez hrane, barem jedan sat prije ili dva sata nakon obroka (vidjeti dio 5.2).
PFS Overall ITT 
PFS Sveukupna ITT
HR = hazard ratio; ITT = intent to treat; PFS = progression-free survival; CR = complete response; PR = partial response. 
HR = omjer hazarda; ITT = namjera liječenja; PFS = preživljenje bez progresije; CR = potpuni odgovor; PR = djelomični odgovor.
Sixty-six per cent of placebo patients received post-study therapy compared to 30% of pazopanib patients. 
Šezdeset šest posto bolesnika iz placebo skupine je primalo terapiju nakon ispitivanja u usporedbi s 30% bolesnika iz pazopanib skupine.
If the potential benefit of reinitiating pazopanib treatment is considered to outweigh the risk for hepatotoxicity, then reintroduce pazopanib at a reduced dose of 400 mg daily and perform serum liver tests weekly for 8 weeks. 
Ako se smatra da je moguća korist od ponovnog uvođenja pazopaniba veća od rizika od hepatotoksičnosti, pazopanib treba ponovno uvesti u smanjenoj dozi od 400 mg na dan te provjeriti jetrene enzime u serumu svakog tjedna tijekom 8 tjedana.
Since vascular endothelial growth factor (VEGF) inhibitors may impair wound healing, treatment with pazopanib should be stopped at least 7 days prior to scheduled surgery. 
Kako inhibitori vaskularnog endotelnog čimbenika rasta (VEGF; engl. vascular endothelial growth factor) mogu negativno utjecati na cijeljenje rana, terapiju pazopanibom treba obustaviti barem 7 dana prije predviđenog operacijskog zahvata.
Adults The recommended dose of pazopanib for the treatment of RCC or STS is 800 mg once daily. 
Odrasli Preporučena doza pazopaniba za liječenje RCC-a ili STS-a je 800 mg jednom dnevno.
- The other ingredients in the 200 mg and 400 mg tablets are: hypromellose, macrogol 400, magnesium stearate, microcrystalline cellulose, polysorbate 80, povidone (K30), sodium starch glycolate, titanium dioxide (E171). 
- Drugi sastojci u tabletama od 200 i 400 mg su: hipromeloza, makrogol 400, magnezijev stearat, mikrokristalična celuloza, polisorbat 80, povidon (K30), natrijev škroboglikolat, titanijev dioksid (E171).
It cannot be excluded that pazopanib will affect the pharmacokinetics of substrates of OATP1B1 (e.g. statins, see “Effect of concomitant use of pazopanib and simvastatin” below). 
Ne može se isključiti mogućnost da pazopanib utječe na farmakokinetiku OATP1B1 supstrata (npr. statini, vidjeti ispod „Učinak istodobne uporabe pazopaniba i simvastatina“).
Patients over 60 years of age may be at greater risk for mild (>3 x ULN) to severe (>8 x ULN) elevation of ALT. 
Bolesnici stariji od 60 godina mogu biti pod većim rizikom od blagog (>3 x GGN) do teškog (>8 x GGN) povećanja ALT-a.
The usual dose is two Votrient 400 mg tablets (800 mg pazopanib) taken once a day. 
Uobičajena doza je dvije Votrient 400 mg tablete (800 mg pazopaniba) uzete jednom dnevno.
Infections occurring while you take Votrient may possibly become serious. 
Postoji mogućnost da infekcije koje se jave za vrijeme uzimanja lijeka Votrient postanu ozbiljne.
The primary objective of the study was progression-free survival (PFS assessed by independent radiological review); the secondary endpoints included overall survival (OS), overall response rate and duration of response. 
Primarni cilj ovog ispitivanja bilo je vrijeme bez progresije bolesti (PFS ocijenjeno od strane neovisnog radiološkog pregleda); sekundarne mjere ishoda uključivale su sveukupno preživljenje (OS), sveukupnu stopu odgovora i trajanje odgovora.
Posterior reversible encephalopathy syndrome (PRES)/Reversible posterior leukoencephalopathy syndrome (RPLS) 
Sindrom reverzibilne posteriorne encefalopatije (PRES)/Sindrom reverzibilne posteriorne leukoencefalopatije (RPLS)
The performance status (ECOG) was similar between the pazopanib and placebo groups (ECOG 0: 42% vs. 41%, ECOG 1: 58% vs. 59%). 
ECOG status je bio sličan između grupa s pazopanibom i placebom (ECOG 0: 42% u odnosu na 41%, ECOG 1: 58% u odnosu na 59%).
The safety and pharmacokinetics of pazopanib in patients with moderate to severe heart failure or those with a below normal left ventricular ejection fraction (LVEF) have not been studied. 
Sigurnost i farmakokinetika pazopaniba u bolesnika s umjerenim do teškim zatajenjem srca ili u onih s ejekcijskom frakcijom lijeve klijetke (LVEF) ispod normale nisu ispitivane.
Gastrointestinal (GI) perforations and fistula 
Gastrointestinalne (GI) perforacije i fistule
In vitro, pazopanib inhibited human organic anion transporting polypeptide (OATP1B1). 
In vitro, pazopanib je inhibirao humani organski anionski transportni polipeptid (OATP1B1).
Votrient can, on rare occasions, cause lung inflammation (interstitial lung disease, pneumonitis), which in some people can be fatal. 
U rijetkim slučajevima Votrient može uzrokovati upalu pluća (intersticijsku bolest pluća, pneumonitis), koja u nekih osoba može imati smrtni ishod.
‘Other STS' subgroups 
„Ostale STS“ podgrupe
Furthermore, inhibition of BCRP and P-gp by pazopanib in the gastrointestinal tract cannot be excluded. 
Nadalje, ne može se isključiti inhibicija BCRP-a i P-gp-a od strane pazopaniba u gastrointestinalnom traktu.
Rare side effects (may affect up to 1 in 1,000 people): - inflammation of the lung (pneumonitis) 
Rijetke nuspojave (mogu se javiti kod manje od 1 na 1000 ljudi): - upala pluća (pneumonitis)
There are no adequate data from the use of pazopanib in pregnant women. 
Ne postoje adekvatni podaci o primjeni pazopaniba u trudnica.
Effects included reduced female fertility, increased pre- and post-implantation loss, early resorptions, embryo lethality, decreased foetal body weight and cardiovascular malformation. 
Učinci su uključivali smanjenje ženske plodnosti, povećan gubitak ploda u pre- i postimplantacijskom razdoblju, ranu resorpciju, letalitet embrija, smanjenje fetalne tjelesne mase i kardiovaskularne malformacije.
†Treatment-related adverse reaction reported during post-marketing period (spontaneous case reports and serious adverse reactions from all pazopanib clinical studies). 
†Nuspojave povezane s liječenjem prijavljene nakon stavljanja lijeka u promet (spontane prijave i ozbiljne nuspojave iz svih kliničkih ispitivanja s pazopanibom).
Outcome 
Ishod
In a Phase II study of 225 patients with locally recurrent or metastatic clear cell renal cell carcinoma, objective response rate was 35% and median duration of response was 68 weeks, as per independent review. 
Prema neovisnoj procjeni, u ispitivanju faze II u 225 bolesnika s lokalno recidivirajućim ili metastazirajućim karcinomom bubrega svijetlih stanica, objektivna stopa odgovora bila je 35%, a medijan trajanja odgovora bio je 68 tjedana.
g Cardiac dysfunction events - includes Left ventricular dysfunction, Cardiac failure and Restrictive cardiomyopathy h Frequency is based on adverse events reported by investigators. 
g Slučajevi disfunkcije srca - uključujući disfunkciju lijevog ventrikula, zatajenje srca i restriktivnu kardiomiopatiju h Učestalost se temelji na nuspojavama koje su prijavili ispitivači.
Clinical studies of pazopanib in combination with pemetrexed (non-small cell lung cancer [NSCLC]) and lapatinib (cervical cancer) were terminated early due to concerns over increased toxicity and/or mortality, and a safe and effective combination dose has not been established with these regimens. 
Klinička ispitivanja pazopaniba u kombinaciji s pemetreksedom (rak pluća nemalih stanica [NSCLC]) i lapatinibom (karcinom vrata maternice) su prekinuta ranije uslijed zabrinutosti zbog povećane toksičnosti i/ili smrtnosti, te sigurna i učinkovita kombinacija doza nije ustanovljena za ove režime liječenja.
In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in various animal models, and the growth of multiple human tumour xenografts in mice. 
In vivo, pazopanib je u plućima miša inhibirao VEGF-induciranu VEGFR-2 fosforilaciju, angiogenezu u različitim životinjskim modelima i rast multiplih ljudskih tumorskih ksenograftova u miševa.
Votrient can affect heart rhythm which in some people can develop into a potentially serious heart condition known as torsade de pointes. 
Promjene srčanog ritma (produljenje QT intervala) Votrient može utjecati na srčani ritam, što se kod nekih ljudi može razviti u potencijalno ozbiljno stanje srca poznato kao torsade de pointes.
Votrient can cause problems with your liver which may develop into serious conditions such as liver dysfunction and liver failure, which may be fatal. 
Votrient može uzrokovati probleme s Vašom jetrom koji se mogu razviti u ozbiljno stanje kao što je poremećaj funkcije jetre i zatajenje jetre, koje može imati smrtni ishod.